Merck announces new operating structure in Human Health business

Merck (MRK) announced changes in the structure of its Human Health organization. Merck is organizing its Human Health business into an Oncology Business Unit and a Specialty, Pharma & Infectious Diseases Business Unit. In support of the new Human Health Business Unit structure, Jannie Oosthuizen has been appointed executive VP and President, Oncology and MSD International. Oosthuizen most recently served as SVP and President, Merck Human Health U.S., where he oversaw P&L, strategy and commercialization for Merck’s portfolio in the U.S. In addition, Brian Foard will join the company as EVP and President, Specialty, Pharma & Infectious Diseases, effective March 2. Foard most recently served as EVP and head of Specialty Care Business Unit at Sanofi. Before joining Sanofi, Foard spent almost two decades with Galderma, a Swiss pharmaceutical company. Foard and Oosthuizen will both report to CEO Robert Davis and serve as members of the executive team. Chirfi Guindo has been appointed EVP, Strategic Access, Policy & Communications and will continue serving as a member of the executive team. Guindo most recently served as SVP and Chief Marketing Officer.